SEC Form 4 · accession 0001209191-18-010939
KYNTRA BIO, INC. · KYNB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kalevi Kurkijarvi
Director
Period of report
Feb 15, 2018
Accepted (ET)
Feb 16, 2018 · 5:40 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000921299
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 15, 2018 | M | 6,000 | $2.90 | A | 26,000 | D | |
| Common StockF2 | Feb 15, 2018 | S | 4,900 | $55.56 | D | 21,100 | D | |
| Common StockF3 | Feb 15, 2018 | S | 1,100 | $56.25 | D | 20,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $2.90 | Feb 15, 2018 | M | 6,000 | D | — | Jun 9, 2020 | Common Stock | 6,000 | 0 | D |
Explanation of responses
- F1Shares sold pursuant to a 10b5-1 Plan.
- F2The shares were sold at prices ranging from $55.00 to $55.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3The shares were sold at prices ranging from $56.02 to $56.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4Fully vested.